Cargando…
Comparison of efficacy and pharmacoeconomics of two Helicobacter pylori eradication regimens in peptic ulcer disease
BACKGROUND: Helicobacter pylori, the cause of most peptic ulcer diseases, infects approximately 50% of the population worldwide. Indian data on cost and effectiveness of the standard first-line therapies for H. pylori eradication are scarce. Thus, the present study was aimed at comparing the cost an...
Autores principales: | Kubra Hussaini, Syeda Zaineb, Humaira Hussaini, Syeda Zaineb, Yasmeen, Ruheena, Unnisa, Bader, Syed, Aamir Ali Asgar, Khan, Md Nematullah, Hassan, Syed Ibrahim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799951/ https://www.ncbi.nlm.nih.gov/pubmed/29430411 http://dx.doi.org/10.4103/picr.PICR_99_16 |
Ejemplares similares
-
Pharmacoeconomics - Determiniation of the Cost-Effectiveness of Helicobacter Pylori Eradication
por: Curtiss, Frederic R.
Publicado: (2003) -
Saliva Secretion and Efficacy of Helicobacter Pylori Eradication in Peptic Ulcer Patients
por: Vahedi, M., et al.
Publicado: (2011) -
Hybrid Therapy Regimen for Helicobacter Pylori Eradication
por: Song, Zhi-Qiang, et al.
Publicado: (2016) -
Adding diclofenac to Helicobacter pylori eradication regimen
por: Emami, Mohammad Hasan, et al.
Publicado: (2015) -
Antral Helicobacter Pylori Infection, Hypergastrinemia and Peptic Ulcers: Effect of Eradicating the Organism
por: Park, Sill Moo, et al.
Publicado: (1993)